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Abstract
In recent years, a rapidly increasing collection of investiga-
tive methods in addition to changes in diagnostic criteria 
for dementia have followed “high-tech” trends in medicine, 
with the aim to better define the dementia syndrome and 
its biological substrates, mainly in order to predict risk prior 
to clinical expression. These approaches are not without 
challenge. A set of guidelines have been developed by a 
group of European experts in population-based cohort re-
search through a series of workshops, funded by the Joint 
Program for Neurodegenerative Disorders (JPND). The aims 
of the guidelines are to assist policy makers and researchers 
to understand (1) What population studies for ageing pop-
ulations should encompass and (2) How to interpret the 
findings from population studies. Such studies are essential 
to provide evidence relevant to the understanding of 
healthy and frail brain ageing, including the dementia syn-
drome for contemporary and future societies by drawing 
on the past. © 2020 The Author(s)  
Published by S. Karger AG, Basel
his article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modiied material requires written permission.
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Background
Why a Focus on Brain Ageing and Dementia?
There has been a global increase in the age of our pop-
ulations, resulting in a rise in the number of people af-
fected directly and indirectly by dementia. The personal 
and socioeconomic burdens for dementia sufferers and 
their caregivers are significant as are the costs to society 
as a whole. Indeed, in 2008, the estimated cost of demen-
tia in the EU was EUR 177.2 billion and by 2030 this figure 
is predicted to rise to over EUR 250 billion [1, 2]. The 
global cost of dementia care in 2015 was estimated to be 
in the region of USD 818 billion, approximately 1% of 
global gross domestic product with the largest proportion 
of this cost (70%) being spent on informal, social, and di-
rect medical care. It is for this reason dementia is a major 
public health challenge and has been recognized as a glob-
al public health priority by government and nongovern-
ment (i.e., World Health Organisation and Alzheimer’s 
Disease International) organizations [3].
Context
Why a Focus on Brain Ageing and Dementia?
In order to mitigate the forecasted dementia burden 
over the next 3 decades, from 50 million people in 2017 
to 131.5 million by 2030, there has been an increase in 
research into up stream prevention, early detection to de-
lay or avert onset, and interventions to support those with 
dementia once the clinical syndrome is present. To 
achieve this requires a deep understanding of the nature 
of the dementia syndrome – in whom it occurs, what the 
risk profiles are, and what the evidence of impact is of any 
changes in natural history that might be effected through 
societal action or individualized interventions. 
Substantial evidence on risk from population-based 
 cohort studies has emerged suggesting that age-specif-
ic  risk for dementia across generations has declined in 
high-income countries (including the USA, UK, and the 
Netherlands). There are also some promising findings 
from trials of interventions on risk profiles, although with 
limited impact. Through highly selected volunteer cohorts 
the ability to stage the neurobiological markers associated 
with clinicopathological Alzheimer’s disease diagnosis is 
emerging with intensive phenotyping [4]. It is vital that 
policy makers, funders, and researchers understand the 
place of volunteer cohorts in the context of population-
based studies. Outputs from our Joint Program for Neuro-
degenerative Disorders (JPND) workshops set out the dis-
cussions and motivation for the creation of the guidelines 
for undertaking new cohort studies which form this paper. 
Why Will the Guidelines Be Useful?
In the last decades, there has been an intense interest 
in the exact numbers of people in individual nations who 
“have dementia,” with it becoming a mantra used by gov-
ernments, charities, researchers, and businesses (e.g., “ev-
ery 3 s globally a person develops dementia”). The ques-
tion is, where do these data come from when they are not 
available from routine data in any country globally? Gov-
ernments and various constituencies interested in, or 
with a need to, promote awareness of dementia rely on 
approximate or estimated numbers, guided by expert 
opinion, for prevalence (i.e., the number of cases of a dis-
ease or condition in a given population), incidence (the 
number of new cases of a disease or condition that occur 
over a defined period of time in a given population), nat-
ural history, and risk as almost always robust population-
based data are unavailable. Basing policy upon these esti-
mates is likely, unless done with true knowledge of how 
the estimations are created, to result in a mismatch of 
resourcing with true need. 
In the last few decades we have seen dramatic increas-
es in life expectancy globally, with primary prevention of 
chronic conditions such as cardiovascular disease ac-
counting for a significant portion of this increase. Despite 
this ageing of the population, recent population-based 
European studies, which have reported on dementia oc-
currence using stable diagnostic methods, suggest a sig-
nificant age-specific reduction in dementia prevalence 
(although routine data-based studies reveal stability or an 
increase) [5–10]. This, along with rapidly changing diag-
nostic criteria, sociocultural environments, mass migra-
tion, and generational variation in life course experiences, 
means that governments can no longer assume that de-
mentia itself and the needs of people living with dementia 
remain stable as new generations’ age. 
Global interest in dementia from research and bio-
logical angles over recent years has led to a rapidly in-
creasing armamentarium of investigative methods and 
associated changes in diagnostic criteria, not just for 
manifest dementia but also for earlier phases of the un-
derlying neurodegenerative diseases. Recent changes in 
these diagnostic criteria, in principle designed for re-
search purposes, have incorporated biological measures 
into new diagnostic criteria which seek to define risk in 
people before the expression of a full dementia syn-
drome. The aim is better prediction of dementia and 
eventually early intervention strategies to decrease risk 
or prevent dementia onset. Approaches such as these are 
not without societal implications, for example, health, 
and life insurance. 
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There is a need, indeed obligation, for societies and 
those who determine resource allocation, to invest in 
those policies on dementia care and prevention with the 
greatest likelihood of benefit for the population. Further, 
it is essential that such policies address social and gender 
inequality. This means that methods for risk stratification 
promoted for widespread use need to be fully tested in 
relevant populations, with some estimation of cost and 
benefit to truly understand risk prediction specific to the 
context it is to be applied. Development of such policies 
will require the integration of evidence from new ap-
proaches, testing against rigorous standards in relevant 
populations with detailed evaluation of emerging meth-
ods which currently include radioactive ligand imaging 
(potentially with multiple types of ligand and repeatedly 
across age). 
These new approaches have largely been developed in 
highly selected volunteer and tertiary setting clinical pop-
ulations. Accompanying these developments is a particu-
lar need to assess performance of any new emerging and 
sufficiently robust approach in population representative 
studies in order to assess their clinical utility, impact, 
harms, and costs.
21st Century EURODEM Workshop Framing
In 2015, a consortium of international dementia epi-
demiology experts was brought together under the JPND 
initiative “working groups to inform cohort studies”. Pri-
or to the initiation of the consortium, many of the mem-
bers had actively contributed to the JPND remit and pro-
duced outputs to inform that call [11–14]. The first meet-
ing of the consortium focused on cohorts and shared 
experience of investigators who have conducted popula-
tion-based studies focused on cognition and dementia in 
Europe both historically (e.g., Cognitive Function and 
Ageing Study I [CFAS I], Cardiovascular Risk Factors Ag-
ing and Dementia and Gothenburg studies) and current-
ly (e.g., Rhineland, LIFE, CFAS II). From these discus-
sions, two themes emerged, Descriptive Epidemiology 
and Mechanistic Analysis. 
Descriptive Epidemiology and its methods requires an 
assessment of definitions of disorders, purpose of diagno-
ses, the implications of a positive diagnosis, and the abil-
ity to synthesize findings across differing geographies, 
populations, and time. Epidemiology provides a context 
for health and social care provision at both national and 
local levels including resource allocation. It also supports, 
through the knowledge gained and numbers estimated, 
development of simple analytical models, which can be 
used to predict the future clinical, economic, and social 
needs associated with neurodegenerative diseases and the 
possible impact of population change, whether through 
intervention or not. This is illustrated by CFAS in the UK, 
which has been used widely for estimating the future 
numbers of people with dementia as well as how these 
might be affected by changes in risk profiles at earlier 
ages. 
Analysis to elucidate disease mechanisms, important 
for determining clinical outcomes, needs to take into con-
sideration the methodological and analytical methods 
used to assess both risk and resilience factors. Attempts 
to stratify risk using new criteria for early disease stages 
with or without clinical symptoms have tended to assume 
that such factors are stable across time and populations – 
an assumption that is not necessarily true, unless these 
have been tested in robust empirical analyses in a range 
of population-based samples. Risk stratification within 
clinical settings is seen as valuable; however, the evidence 
base to date is not yet sufficiently robust and has many 
shortcomings [15, 16]. 
In the population, cognition and cognitive change is a 
continuum. Over the last decades, attempts to pin down 
specific boundaries as to what constitutes dementia have 
created a moving field. The focus on dementia, without 
thinking about broader mechanistic analyses for brain 
failure, has created an emphasis which suggested that sin-
gle proteins might be the answer to most dementia. 
The recent strong move toward amalgamation of exist-
ing datasets, more or less harmonized, is conceptually at-
tractive. Harmonization and combined analyses can 
however pose challenges, although traditional meta-anal-
ysis can be strengthened through consistent methodolog-
ical approaches in the primary research cohorts them-
selves such as was the case with the earlier EURODEM 
linked incidence studies. 
The creation of large samples for analyses may be pos-
sible through the pooling of datasets, however, ignoring 
their provenance is dangerous to later value. Once dis-
connected from knowledge of their generation, data can 
become misleading. The “Big Data” revolution, which in-
cludes vast amounts of data on individuals (-omics) as 
well as potential linkages to health and social care records 
and other internet data (purchases, movement, location), 
needs to be led by those with deep population engage-
ment and understanding. This includes epidemiologists 
and experts within disciplines related to population 
health and well-being with support from bio-informati-
cians, machine learning/artificial intelligence experts, 
and the biomedical community. At present, efforts are 
not balanced in this way with the danger of heaping the 
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rich rainbow of cohort resources into a single bucket of 
brown sludge from which little can be gleaned (“Rainbow 
in a Bucket”).
Artificial intelligence is increasingly making its way 
into clinical practice (e.g., in diagnostics and imaging); 
however, its reliance on historical data, which are based 
on biased data generation or clinical practices, could cre-
ate or perpetuate biases which may worsen patient out-
comes. By strategically deploying AI and carefully select-
ing underlying data, algorithm developers can mitigate 
AI bias. Addressing bias could allow AI to reach its fullest 
potential by helping improvement of diagnosis and pre-
diction while protecting patients [17].
Cohort studies can be a key contributor to the evalua-
tion of novel diagnostic and prediction methods being 
developed in clinical settings. In order to understand the 
implications of rolling out such novel diagnostic meth-
ods, existing studies can provide a valuable base to test 
utility and pitfalls of implementation. Recent meta-anal-
yses have highlighted inconsistent, and at times, poor 
methodological quality for validation of new diagnostics 
and prediction tools. In reaction to this, the Cochrane 
Collaboration developed the STARDdem criteria for di-
agnostic studies in dementia. A similar approach to qual-
ity assessment for prediction is also required for observa-
tional cohort studies specific to the array of potential risk 
and protective factors investigated as predictors from de-
mentia cohorts [18]. 
In order to maximize investment in large studies with-
out clinical diagnostic outcomes, but with well-measured 
cognition, particularly with regards to functional and so-
cial change, a good and integrated understanding of pre-
viously conducted research is required. 
Historical investment in cohort studies of populations 
in Europe has undoubtedly strengthened the continent in 
the field of ageing (and dementia) research; however, it is 
apparent that there are still many unanswered and emerg-
ing questions. Prominent among these are whether de-
mentia occurrence is changing as global population age is 
shifting; whether clinical profiles of dementia and their 
associated endobiological phenotypes are changing and 
will continue to change further; whether the relationship 
between diagnosis, disability, dependence, and survival as 
outcomes is changing; and what the interplay of relevant 
risk factors is at earlier life stages. 
Uniquely placed to address these questions in a way 
that can be compared across time periods and geogra-
phies are population representative cohort studies. These 
are not simple to finance, design, run, and sustain. As 
such, there is a compelling need to both ensure maximi-
zation of the value of existing data and argue for invest-
ment into specific new studies which can address ques-
tions relevant to contemporary and future populations at 
intermittent time periods, across geographies, and com-
munities, most notably in areas where there is little or no 
contemporary or historical data. 
These recommendations and guidelines aim to inform 
a wide range of audiences including researchers entering 
the area of dementia. They aim to assist dementia re-
searchers understand what a population representative 
perspective is, where it fits, and critically, will provide the 
background framing for policy makers and funders who 
make decisions about the balance of research funding 
available to existing and new work, across biomedical and 
policy relevant domains. The guidelines cover all ele-
ments of the evolution of the dementia syndrome and 
cognitive impairment which does not meet criteria for 
dementia (whether mild cognitive impairment or the 
wider category of non-demented cognitively impaired).
Basic Orientation
What Are Population Representative Cohort Studies?
The definition of a population representative cohort 
study is not straightforward; here, the distinction be-
tween population derived and population representative 
can help (Table 1). While many cohort studies are popu-
lation derived, relatively few are population representa-
tive. 
Few volunteer cohorts across the life course have ro-
bust links to their original sampling frame; however, they 
have provided the bulk of our knowledge relating to risk 
factors for and the evolution of dementia within a given 
cohort. Without these links to the original sampling 
frame, such studies provide less evidence for the transla-
tion of findings back into the whole population of inter-
est. Conversely, there are also limitations of population 
representative cohorts, which typically suffer from higher 
attrition rates than their volunteer counterparts and this, 
if not taken into account using appropriate biostatistical 
methods, can lead to biased findings on incidence rates 
and risk estimation.
What is meant by the word population and the rela-
tionship between personalized and collective approaches 
requires new scrutiny. This relationship is extremely im-
portant in the fields of dementia research and public 
health, as it is used as the basis for decision making re-
garding the balance of investment for current and future 
populations. There is a need in population descriptive 
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work to consider which groups are missed and underrep-
resented, even in studies that have been conducted with a 
view to be population representative. 
Full exploration into research findings generalizability 
is rare, with most findings assumed to be generalizable 
from one setting to another. The dementia research field 
has an abundance of such examples; with many papers 
citing the need for their findings to be translated beyond 
the populations in which the evidence was generated. 
Sometimes these findings will be robust, often they will 
not. This lack of awareness of evidence provenance and 
generalizability is crucially important from a public health 
perspective and is likely to be a contributing factor in the 
repeated lack of replicability of findings in new samples. 
However, lack of replicability can also be attributable to 
genuine differences between populations across geo-
graphical areas and time periods; findings which could 
present new research questions [19]. 
Further critical areas of importance are the definitions 
of the original population sampling frame that is, who is, 
and who is not, included. This is particularly important for 
hard to reach or underserved, vulnerable populations and 
often includes those in care settings. Response rates and 
attrition are also critical in assessing the value of research 
in terms of generalizability and population meaning.
Since the development of genomic and biomarker 
measurement, the need for representative populations in 
studies has been neglected. Convenience samples are of-
ten studied without much attention being paid to selec-
tion bias. This does not mean population representation 
no longer matters. The poor performance of almost all 
studies of biomarkers when drawing on population ap-
proach is a major concern. The disconnection between 
tertiary clinic practice and performance in “usual” popu-
lations is not intuitive and poorly understood. It does not 
receive the attention it should, given the cost and poten-
tial harm to individual patients if tests developed on one 
population are applied to another in which the test has 
not been validated. A good example of this premature 
translation across settings from research to clinical might 
be amyloid imaging, which has not fared well in scrutiny 
of how robust it is through the Cochrane evidence review 
[20]. 
Current and future cohort studies, while highly valu-
able alone, can be further enhanced through the harmoni-
zation of data into a single structure for analyses. Harmo-
nization is, however, extremely challenging and is more 
often an aspiration rather than achieved, other approach-
es are possible and can be more efficient [21]. It is impor-
tant when designing new cohort studies to consider an-
choring points to past studies and ensuring the use of con-
sistent methodological approaches which will allow for 
harmonization and comparisons across time and space.
What is needed is strong support from policy makers 
and dementia researchers embarking on new work to in-
tegrate and interpret the gaps in current knowledge of the 
types and value of existing research, including epidemio-
logical principles, approaches, and the role of harmoniza-
tion and cross-study collaborations. 
What Are We Actually Studying and Why?
In all research, including those making investments 
and those interested in current and future public health 
and population meaning we must always keep in mind 
the questions “what exactly is the thing we are studying?” 
and “how relevant is this to the societal concern of de-
mentia and associated states in current and future popu-
lations?” In other words, if a new disease concept such as 
“pre-clinical Alzheimer’s disease” leads to an epidemic of 
a diagnosis but one which has a benign prognosis, what 
does this mean for the societal “burden” of dementia and 
for the way in which an ageing society views itself?
Table 1. Population derived versus population representative
Population derived Population representative
Sampling –  The original sample is drawn from a population,  
no matter how unrepresentative the final sample is 
after recruitment and subsequent follow-up waves
–  Recruitment is from a known population base. Can support purposeful 
sampling from geographical areas or other defined clusters
Key
features
–  Volunteer studies examples include UK BioBank –  Provenance of recruited sample is known and can be mapped back in a 
robust statistical manner to the original population with appropriate  
acknowledgement of potential bounds of uncertainty
–  Some information on the unseen population should ideally be available. 
This can be in the form of aggregated contextual knowledge for the given 
population as a whole
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Dementia is a clinical syndrome, a valuable diagnostic 
label with a long history. Since diagnostic criteria were in-
troduced these have moved from discursive texts to more 
specific lists of signs and symptoms. Early definitions that 
incorporated knowledge about vascular factors and ageing 
itself became replaced in the era of drug discovery by an 
emphasis on clinically diagnosed  Alzheimer’s disease, 
with its assumptions of pure underlying neuropatholo-
gies, and focus on particular proteins. More recently, this 
has been complemented by the rediscovery of vascular 
contributions to dementia, Lewy Bodies, and Parkinson’s 
Disease, the multietiology of the relatively earlier onset 
frontal-temporal dementias and, most recently, the con-
tribution of TDP-43 to not only frontal-temporal demen-
tias but also hippocampal sclerosis. Knowing the extent to 
which diagnoses in cohort and specifically selected popu-
lation studies differ from real life settings is crucial to de-
termining the potential of any particular study to provide 
valuable insights into how risk reduction and prevention 
need to be tailored for populations, particularly those with 
the greatest occurrence of dementia.
Some have suggested that population studies of de-
mentia are unnecessary, and that we can rely on clinical 
records or indeed forms of machine learning. If we had 
accurate, valid, reliable relationships between real time 
life and the data that are captured on each of us in many 
different places, including health and social care, this may 
be possible. However, this is not the case. Such data are 
biased or inaccurate, and it is essential that diagnostic as-
certainment bias is considered if systems are to rely on 
routine data. 
There are changes across time in the way in which di-
agnoses are made, and by whom. If diagnoses rely on clin-
ical consensus and changing availability and interpreta-
tion of data, whether routine or from dedicated surveys, 
it is possible for diagnostic creep and boundary shifts to 
be introduced creating an illusion of change where there 
is none. In a study that is testing for change across time it 
is essential that the same symptoms give the same diag-
noses for person number 1 and 1,000 measured at time 0 
and 5. The more invasive and less typical the diagnostic 
ascertainment the more likely that heterogeneity in diag-
nosis is removed, but at the cost of increased participant 
burden and attrition bias into diagnostic phases. 
Different approaches to defining dementia adversely 
affect comparability of data across time and cross section-
ally between, for example, geographies. In this regard, 
capturing social, functional, and cognitive outcomes and 
avoiding medical categorizations can overcome such in-
consistencies although it introduces a welcome focus on 
what is meant by cognitive and functional decline, with 
the latter’s relationship to context and comorbidity key 
too. Of greatest value are prospective cohort studies 
which apply consistent measurements of outcomes; how-
ever, cross-sectional studies are still of value if they accu-
rately relate to a meaningful denominator [15].
Deep knowledge of population incidence and preva-
lence, including careful phenotyping across age, gender, 
education, culture and socioeconomic status, allows for 
better scrutiny of the research arising in more selective 
settings and the claims are made based on the results. Pre-
dictions can be tested with known outcome data and 
models improved. Biological metrics have been promot-
ed to establish who in the population might be at risk of 
future dementia syndrome; however, these particular 
metrics cannot be assumed to either be sufficient to avert 
the dementia syndrome or indeed to replace knowledge 
of the lived life of individuals within their social and cul-
tural contexts. 
Taking a consistent approach to measurement allows 
trends in incidence and prevalence to be monitored. One 
way of doing this could be through the creation of a sen-
tinel population in anchored clinical centers across 
 Europe which collect a minimum core data set of longi-
tudinal assessment from extant and newly created gen-
erational cohorts. In order to inform science and policy, 
as the cohorts represented at the workshop have already 
done, these would need to consider dementia develop-
ment in the context of ageing, including noncognitive in-
fluences on morbidity in dementia, for example, social, 
physical, and economic factors as well as traditional cog-
nitive approaches. 
Cohorts with diverse populations allow for stratifica-
tion and risk assessment that is robust. This in turn can 
be used either within cohort studies or in new popula-
tion-based trials to test the potential for changes in trajec-
tories. At present, the pressure to measure biological met-
rics in people with and without symptoms that might in-
dicate early change has had a profound impact on some 
clinical services such that biomarker salience in diagnos-
tic pathways is becoming the norm in settings, blurring 
the routine with the research agenda. This is clearly pre-
mature, with little evidence of real clinical value as yet. 
Demand has been driven by awareness, but without evi-
denced interventions or certainty in prognosis, undertak-
ing such tests in large numbers of people is of poor value 
for health care investments where other evidenced op-
portunities exist to improve health and wellbeing. 
As noted above new research criteria [22] have changed 
the boundaries used in a variety of diagnostic criteria re-
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lated to dementia (mild cognitive impairment with its 
changing definitions and Alzheimer’s disease being key 
examples), and it is important to test systematically, and 
in relevant populations, the impact and meaning of such 
changes [23]. An example of the effect of new diagnostic 
criteria is that we do not know what the association and 
progression of novel biomarkers are in relation to disabil-
ity and loss of independence. Population-based studies 
are essential to validate or refute their value and ensure 
that findings from the bench can be translated to the in-
dividual.
As well as the focus on the outcome of dementia, trends 
in the factors associated with risk for or protection from 
dementia are required from populations across the life 
course, for example, education and prevalence of smok-
ing. Changes in these risk factors can be modeled for their 
impact on future dementia and the impact tested directly 
against the potential for therapeutics. Given the lack of 
effective treatments for any dementia, even those of early 
onset, such modeling can be done to test what would the 
impact of a medication have to be and at what age to re-
duce dementia risk by matching amounts to the life course 
risks already known [24, 25]. New findings can then be 
scrutinized to see how they measure up to these known 
life course risks. 
Although dementia as a syndrome can be analyzed as 
a single concept for certain purposes related to policy, 
health services, and public health, research does need to 
reflect its enormous heterogeneity. Researchers need to 
be aware of this heterogeneity, how the cohort studies 
represent dementia, and how their research fits into this. 
For cohort studies that aim to compare across geography 
and time, it is absolutely essential that there is consisten-
cy in approaches to study diagnoses, so that diagnostic 
drift and clinical shifts do not introduce systematic bias. 
What Is the Role and Value to Society of Population 
Representative Studies in Primary, Secondary, and 
Tertiary Prevention? Setting the Agenda
The answer to this question hinges on the gaps in de-
mentia research. While the research agenda is heavily in-
fluenced by those in clinical and biomedical fields, it is 
also determined by funders, politicians, and interested 
groups such as pharma, diagnostics, and technological in-
novation leaders, charities, patients, their families, carers, 
and the media. These constituents use epidemiological 
evidence of the size of the dementia “epidemic” or “tsu-
nami” to justify particular activities. Rarely has there been 
evidence of reflection as to whether their promotional 
work actually maps onto the population evidence noted 
above. An example is the fact that dementia is commonest 
in the oldest age groups, but that imaging studies are fo-
cused on the smaller populations at higher risk in young-
er age groups. Recommendations for clinical practice for 
all dementias are often based on knowledge from memo-
ry clinics and specialist centers ignoring the fact that most 
people with dementia have multiple comorbidities and 
would not pass through such clinical services. 
One activity that attempted to counterbalance these 
perspectives is that of the James Lind Alliance [26]. This 
is a UK-based exercise exploring what the more general 
public consider as research priorities. It was developed in 
response to the fact that so little research actually address-
es what people see as the need for evidence in many areas 
of challenges to health and wellbeing. The James Lind Al-
liance [27] is one in which the people, a much wider audi-
ence than general in terms of who drives the pattern of 
research funding and decision making, have a chance to 
pitch their perception on the questions unanswered by 
research. In the dementia-focused exercise, responses 
were distilled and synthesized into answerable questions, 
the literature searched on whether robust evidence exists 
and if not, these uncertainties were confirmed and a pro-
cess of prioritization using established methodology fol-
lowed. This process was conducted for primary, second-
ary, and tertiary prevention with the public and wider 
professional and institutional groupings. Over 4,000 in-
dividual questions were submitted, and all the questions 
were framed in terms of the public health prevention 
model [28]. Such exercises are being conducted in other 
countries too (e.g., Canada). 
A public health research approach can meet these un-
certainties as it is inherently multidisciplinary and relates 
to relevant populations and disorders in their societal 
context. Such work emphasizes the limited progress made 
with studies such as biomarkers in understanding their 
general limited specificity. Well-designed population 
representative cohort studies can address the urgent con-
cern that, in pursuing the diagnostics currently being 
promoted in some clinical practices, we might be labeling 
a large group of people as suffering from a “disease” who 
would not develop symptoms in their lifetimes. 
Prevention
Primary Prevention
The definition of primary prevention depends on per-
spective. If modifiable risk factors for the development of 
dementia are identified, and treatment of these will reduce 
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risk of developing dementia, this would meet the defini-
tion of primary prevention. However, if this concerns bio-
markers that are a marker of the earliest pathological man-
ifestations in the development of a later clear-cut condi-
tion, such as cervical dysplasia, this is not primary but 
secondary prevention. We have compelling evidence of 
primary prevention at population level in many countries 
that has led to age-specific reduction of dementia risk [29], 
but without very clear knowledge of what life course fac-
tors contributed to/fostered this reduction. 
Many countries now seek to include brain health in 
their health promotion messaging. This has encouraged 
an increase in individuals actively engaging in what they 
perceive to be risk-reducing activities such as physical, 
social, and cognitive activities. Balancing individualistic 
approaches with those for whole populations needs to be 
based on what benefit will be derived for whom. Individ-
ualistic approaches can further increase inequality, al-
ready apparent in dementia risk [7, 30]. Such approaches 
are unlikely to be of value to less advantaged populations 
within and across countries. Trials and long-term natural 
history studies in diverse populations are important in 
this area to inform what can be done in whole popula-
tions, for particular types of societal and individual inter-
ventions [31]. Formal trials are often challenging in con-
texts in which the policy environment is changing, but it 
is important to strengthen methodologies that can evalu-
ate natural experiments rigorously. Clinical conditions 
that constitute dementia risk are already being used in the 
UK health system (“health checks” now include dementia 
as an outcome for people with higher risk through condi-
tions such as diabetes and stroke). 
How do population cohort studies inform primary 
prevention research? Knowledge of whole populations 
informs trials, their designs, and their implementation. 
Population studies can also assist in the evaluation of pri-
mary prevention strategies through modeling and natural 
experiments (such as cohort changes). Estimation of 
treatment effects can be calculated using population data 
[32, 33], and population studies can inform primary pre-
vention through adoption of interventions. Population 
studies also allow for quasiexperimental designs to be 
considered. For instance, the regression discontinuity de-
sign allows for estimation of treatment effects without the 
need for randomization [34].
Various risk factors (e.g., health and lifestyle risks) for 
dementia exert different effects throughout the life course, 
with potential cohort-effects depending on population 
characteristics, cultural context, and era in which data 
were collected. Research to support future prevention 
programs must cover the full spectrum of primary pre-
vention, from targeting at risk groups to the whole popu-
lation. Specific attention should be paid to cohort effects 
and geographical differences influencing the observa-
tional data on which future interventions will be based. 
Secondary Prevention
Secondary prevention concerns any intervention in-
tended to slow down neurobiological processes that are 
part of pathological pathways, and those interventions 
that reduce further cognitive decline in those with cogni-
tive impairment not sufficient to merit dementia diagno-
sis. Biomarkers (CSF, imaging) and early clinical signs 
(such as neuropsychology or psychomotor disturbance) 
have the potential to be the measures that provide such 
detection (as in cancers). The marker needs to be ex-
tremely well understood and its relationship to the disor-
der in question must be very close indeed such that indi-
viduals (of particular age, sex, etc.) with particular metrics 
can be given their prognosis within reasonable bounds of 
uncertainty [35]. If biomarkers that can be obtained in a 
noninvasive, or minimally invasive way, have sufficiently 
good test characteristics (i.e., in terms of sensitivity, spec-
ificity, predictive accuracy, validity, and reliability, etc.) 
in the general population become available, and there are 
very effective treatments for that particular disease such 
that early detection changes natural history with much 
improved clinical outcomes it is conceivable that these 
could also be used for selecting the right target population 
for a secondary prevention program. This needs to draw 
on existing population cohort studies, to understand ful-
ly what the implications of the screening itself would be 
for the particular society. 
Population data on natural history for biomarkers and 
clinical signs, their evolution, and relationship to out-
comes of relevance to populations in which a disorder 
occurs are critical to progress the field of secondary pre-
vention. The settings in which tests are used are extreme-
ly important, for example, prostate-specific antigen per-
forms poorly in primary care but well in secondary and 
tertiary clinical settings. This requires knowledge of bio-
markers in appropriate unselected populations to be 
studied using the proposed measures (usually “validated” 
in selective settings) on a repeated basis to see how well 
those who progress to develop a disorder within a popu-
lation setting are identified by the proposed test or com-
binations of tests. Currently, even programs such as 
breast screening are being evaluated to attempt to make 
them less harmful to those who will not benefit. At pres-
ent, a neglected consideration for secondary prevention 
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is the nature of the evidence base required to justify offer-
ing biomarker screening to any asymptomatic popula-
tions about harms and benefits of any given intervention(s). 
In other words, what is the “offer” to society and an indi-
vidual and what are the potential full costs (financial and 
other) of such an offer. All screening does harm, a fact 
that is relatively underrecognized [36].
Policy for secondary prevention programs must be based 
on robust evidence, and internationally accepted guidelines 
for such screening have been well described by the World 
Health Organisation, the US Preventative Task Force work, 
and the UK’s National Screening Committee [37–39]. Up 
to date population-based studies, including cohort trials, 
are essential for knowledge about how secondary preven-
tion should be implemented once preliminary trials have 
been conducted. Population evidence is crucial in the de-
sign of the research and policy development in this area. 
Tertiary Prevention, Including End of Life
Tertiary prevention means that for those people who 
have presented to health and social care, relevant and ev-
idenced possibilities can be offered. The evidence base 
here is largely developed through trials in clinical and 
other settings, such as care homes and includes any inter-
vention in those who have a diagnosis of dementia. It is a 
key that this also encompasses research about a dignified 
and compassionate approach to end of life care and deci-
sion making. 
Population studies are again relevant as clinical set-
tings do not capture the needs of the population as seen 
in the community. Individuals come and go from clinical 
services and are not then followed up to death. Indeed, 
primary care practitioners will not necessarily see those 
who are well supported within their communities. Re-
search needs to describe the whole population, not just 
Table 2. Prevention types
Prevention type Definition Benefits Considerations Role of population studies
Primary Upstream prevention  
of a disorder or  
disease
occurring
Can be targeted toward whole  
populations, communities, or at 
individual levels
Can be targeted at high risk  
populations based on clinical  
characteristics
Individualistic approach  
to health that may lead  
to a further increase in  
health inequalities
Data from population  
studies contribute to  
models about which risk 
factors have the greatest 
prevalence and potential  
for societal and service  
action
Without longitudinal data 
on risk from population 
representative studies for 
given populations, the  
true potential for primary  
prevention cannot be  
known
Secondary The early detection of  
a disease process
or the risk for a  
disease progressing in 
which the natural  
history is understood 
and well known
Prevention/risk reduction  
programs can be  
opportunistically delivered or  
delivered through screening  
programs
With biological secondary  
prevention the assumption
is that interruption of pathways  
will be beneficial
at later life stages 
Consideration to  
settings in which  
tests are used are  
extremely important
Justification must be  
made regarding offering 
biomarker screening to  
an asymptomatic  
population about the  
harms and  
benefits of any given  
intervention
Population-based studies  
are essential for collecting 
knowledge on how  
secondary prevention  
strategies should be  
implemented
Tertiary The mitigation of a  
disorder once present
Largely developed through trials  
in clinical and other settings.  
Also available on relatively small  
numbers from within cohorts,  
also includes end of life care
Applying costings based 
only on those seen in  
services would not take  
into account the full  
range of need
Population studies are  
required to capture a  
picture of the whole  
population as it is in  
society
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those seen in particular settings in order to understand 
the reality of dementia in populations. Applying costings 
based only on those seen in services to all people with de-
mentia does not take into account the full range of need 
and may well be severely impacted by the unique charac-
teristics of the individuals in such studies. The complete 
picture of the natural history and cost of dementia may 
therefore be inaccurately estimated. Such research in-
forms policy development in an important and unique 
way, relevant to work such as the UKs NICE assessments 
(and similar ones elsewhere in Europe and beyond). Pop-
ulation-based studies provide a background and a poten-
tial resource in which research aimed at tertiary preven-
tion can be developed. Trials that work with this kind of 
approach are more likely to be relevant to the ultimate 
aim of all health research to improve lived lives for the 
population (Table 2).
Guidance on Understanding Existing Data
In order to conduct truly informative integrated anal-
yses with cohort data for the purposes of addressing the 
areas noted above, the following areas as outlined in the 
checklist in Table 3 must be well understood. Quality of 
reporting in these areas is highly variable, but it is in-
creasingly recommended by journals that this is im-
proved. 
Commentary
Most studies will not be able to meet the highest stan-
dards in all of the areas outlines above. However, some 
attempt is warranted, and any findings presented without 
sensitivity analyses to explore the impact of inevitable im-
perfection of all studies should be treated with caution. 
This is because the study will not be able to contribute 
fully to synthesized approaches about whole populations. 
There will be internally valid questions that can be an-
swered without going through this challenging list, but 
these will be divorced from true populations and thus 
their meaning for policy and future populations will be 
unclear. 
Guidance on Repurposing and Establishing New 
Cohorts to Address the Areas Above
If you are planning on establishing a new cohort, first 
of all, assure yourself that the planned new cohort will 
truly have added value to answer specific research ques-
Table 3. Checklist for evaluation of population relevance
Original purpose
Details of the sampling frame, how it was generated, whether it is up to 
date, patterns of migration, and whether it includes care settings
Approach to participants, opt-in, opt-out, incentives, and exhortations
Details of the consent process
Response rates
Where people were interviewed, what they were offered. Uptake of  
different study offerings in terms of detailed phenotyping
What type of person did the interviews, how were they trained, evidence 
of quality control, and was clinical examination involved
Reasons for refusal within the study – gate keepers and proxies,  
individual refusal, specific refusal on questionnaire or investigation 
items, interviews abandoned
Ability to characterise the nonresponders at the population/geographical 
level
Attrition details (moving, death), over time
Further information on those who did not take part – complete or partial 
and if partial what are the characteristics of the people with missing data 
and the missing data themselves
Measures collected – origin of questions, validation if available (against 
what gold standard), whether coding and by design missingness exists
Do the measures include sufficient basic sociodemographic perspectives 
to provide contextual information for assessment of interpretation and 
generalisability?
Was the respondent interviewed alone? Were proxy informants  
involved?
Has there been stability of questions and measures across time? If not, 
how have questions changed and what is the potential implications of 
that change?
If biological samples were collected, are they appropriate to the questions 
being addressed? This includes the way they were taken, who by and how 
were they handled (e.g., immediately and shipped to storage, stored, 
extracted, and analysed)
How have problematic areas such as different IADL and ADL for men 
and women through cultural disability been explored
If routine records were used in follow-up what was the health system at 
the time and what biases/influences could have been introduced for 
example, health service and social policy change?
Have any or all of these factors been examined in any outputs to date?
If yes, is it only to say these might introduce bias or limitations or is 
there further exploration to test which way the bias might go and how 
large it might be?
Have the findings been contextualized using all this information to  
assess what the true value of the outputs are? This means for that  
population, in relation to other known, nonindependent risk factors and 
the potential for population impact is (i.e., meaningful effect sizes rather 
than p values)? This is in contrast to limited publication of narrow  
associations that do not provide context and meaning
ADL, activities of daily living; IADL, instrumental ADL.
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tions. Second, consider if you will have sufficient power 
to answer your specific research questions. Existing co-
horts across generations still have great value to generate 
and test hypotheses about causation, natural history, and 
the relationship between ageing and dementia. However, 
this must be done with nuanced understanding of co-
horts. 
In addition to maximizing the policy and scientific 
value of existing cohorts, as implicit from the discussion 
above, new cohorts are urgently needed for those geo-
graphical areas and social groups where data are de-
cades out of date or no data exist. This is of particular 
concern to Eastern Europe and low- and middle-in-
come countries, which have substantial dementia bur-
dens, but very limited research and health care capacity 
to deal with their ageing populations. Some cohorts will 
have the potential to incorporate experimental and in-
terventional approaches or be able to be used to evaluate 
geographical changes. This has a range of implications 
and considerations for which new guidelines need de-
veloping.
All elements in the above checklist (Table 3) should be 
integrated into the design and collection of data at each 
study wave. Additionally, and depending on context, 
there should be detailed consideration of how inequalities 
and hard to reach communities are being included with 
particular design features appropriate to culture and set-
ting (this will include gender and location of study being 
conducted for some communities). Our core recom-
mended template for undertaking new cohort studies is 
shown in Table 4. 
Guidelines on Research Expertise Requirements
Skill Requirements for Cohorts
Undertaking a new cohort study requires a multidis-
ciplinary team committed to the long-term gathering of 
data and attainment of the highest possible response rate 
based on the decisions taken, whatever the chosen sam-
ple size. The more a study’s inclusion criteria are based 
on onerous and detailed outcome measures, the lower 
the response rate for a complete population is likely to 
be. Studies require expertise in public health, statistics, 
general practice, specialist medical areas, schools of be-
havioral science, study coordinators and managers, in-
terview trainers (if appropriate), as well as professionals 
skilled in communication, IT (if applicable), ethics, and 
data handling. Many skills associated with the set up or 
following of a cohort study are not discipline specific and 
Table 4. Guidelines for undertaking new cohort studies
Aim: Could the question be addressed through existing cohorts or 
other approaches?
Design of study
Knowledge of the population denominator, in as much detail as 
allowed prior to sampling (and usually consent)
Ability to understand reasons for refusal from all participants (as 
much detail as can be allowed within ethical considerations)
Options for levels of participation (clinic visit, home visit,  
internet response, informants, medical/social care record access) 
to increase participation rates
Considerations of enticements or remuneration for participants
Covering sociodemographic features and migration within and 
across regions and countries
Special undertakings for underrepresented populations
Capacity and consent and how to maximize response
Interval of change, how much and how often?
Development of strategies to minimize loss to follow-up
Measurements: Will there be sufficient power to address key  
questions?
Core elements that can be compared across all new studies are 
the key here, such as gender, age, social-economic circumstances, 
chronic diseases, functional impairments, interactions with care 
givers (both formal and informal), and cognitive testing (at least 
broad). Main aspects must have been measured (and reported 
on) in exactly the same way from at least one other study (in the 
geographical region) to provide anchoring of measurements over 
time. This anchoring can be different studies (e.g., measurement 
of education is the same as UK Census, whereas functional  
impairment is the same as another study) but exact replication is 
the key
Measuring risk and compensatory factors across the life course, 
including vascular history and status along with other relevant  
medical conditions
Measuring regular medications, interactions with health services 
and care
Potential to measure easily accessible biological material, for 
example, hair or nails collected appropriately
Questionnaires online or in person, in clinics, or combinations
Potential for computerized testing in addition to existing and 
well-understood testing procedures (not instead of an anchoring  
measure)
Subsets with deeper phenotyping, deeper risk/protection data 
collection. Random subsets with known linkage. Not  
opportunistic, but designed to be maximally informative
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therefore not taught through usual channels. Career de-
velopment can be seriously inhibited for those involved 
in the set up and follow-up of cohorts unless teams are 
well resourced.
Capacity Building for the Future
As stated above, the core skills needed for undertak-
ing cohort studies are rarely taught in any formal arena. 
Years of expertise and knowledge have been captured 
in this contribution by the leading researchers around 
Europe (and internationally) who are at the forefront of 
this type of research. Capacity building presently relies 
on these research groups to fund, and train, new indi-
viduals to be the next generation of population-based 
researchers. Yet funding does not always allow for such 
a transition. It takes years for a study to reach maturity 
from initiation, mostly without core capacity involve-
ment, reliant on single leaders bringing together com-
mitted teams over prolonged periods. New areas need 
developing to meet contemporary challenges, as well as 
to enhance the value of this type of study, including in-
tegration of routine data, biomedical methodology for 
big data and incorporation of new types of such data in 
an informative manner (e.g., geospatial, atmospheric, 
economic, and commercial). Few outside these com-
munities appreciate the detailed issues outlined here. 
Sadly, on the basis of contemporary investment into de-
mentia research [33, 35], this is likely to lead to consid-
erable future wasted investment in research avenues 
which have not been scrutinized fully nor evaluated for 
population relevance and potential for benefit. Training 
basic scientists and policy makers to be able to appraise 
critically (but fairly) evidence from all sources gives ad-
ditional capacity to the community in terms of under-
standing population health.
How to Use These Guidelines
For Funders
Read and think about what the balance of your funding 
is and training for such skills. Long-term vision is re-
quired not only for new cohorts, but in particular for fu-
ture prevention trials.
Policy Makers
Read and apply the evidence provided to you which 
appears to be compelling, and question who and where 
did it come from? What constituencies stand to gain and 
over what time scale?
Journal Editors and Reviewers
Read and think about what you publish, much re-
search is not contextualized and its value is limited be-
cause such careful considerations are not made. Further, 
reviewers are not trained in this and should also take note. 
This will lead to higher quality publications and greater 
use of the excellent guidelines on publication standards 
[16, 39].
Steward of a Cohort which Might Be Population 
Representative
Think about whether you could address some of the 
areas where your study is weaker as there are often other 
sources of information that can help with contextual val-
ue. Think before you overplay your results without con-
sideration of impact.
Cohort Investigator Hopefuls, Applying for Funds
Advise against new cohorts unless you are very clear 
what this new cohort adds to existing cohorts, that is, a 
new era is perhaps not necessarily a strong enough argu-
ment to start a new cohort. Very clear research questions 
are required. Study designs should be determined by a 
statistical power calculation for the main research ques-
tions that the cohort would seek to address (as opposed 
to just collecting as much data as possible to fill a bio-
bank). 
Aim for (inter)national collaboration to start few ma-
jor cohorts, rather than multiple smaller cohorts. Focus 
on research questions. Measure parameters for these spe-
cific research questions in depth, rather than measuring 
a very broad range of parameters.
Other Dementia Researchers of a Non-Population 
Representative Cohort or If You Work in Primary, 
Secondary, and Tertiary Care
Do not translate data of a nonrepresentative sample to 
a wider population without very careful consideration of 
the pitfalls. Aim for proof of concept analyses in highly 
selected populations. Never lose the scope of your cohort: 
highly selected, limited external validity. Look at your 
study through the lens of this guidance and see whether 
you can meet any of the elements. 
Members of the Public or a Charity
Question received statements about the evidence, ask 
where it came from, and how appropriate it is for the chal-
lenges that society grapples with. 
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Discussion
This paper synthesizes a unique expert group’s 
knowledge about a key area for society based on centu-
ries of collective experience of ageing populations and 
dementia. The key messages for researchers and policy 
makers alike working in the area of brain ageing and 
dementia research are that there is no substitute for re-
search, including those studies that are conducted 
across many decades in contrast to other designs that 
are necessarily short term (e.g., RCTs), which has a 
population grounding if research is to fully benefit fur-
ther generations.
We envisage that these guidelines will be of use to re-
searchers and policy makers to assess the value of existing 
and new cohort studies and determine what is required to 
carry out and interpret findings relevant to healthy and 
frail brain ageing, including the dementia syndrome in 
populations. The guidelines provide a framework to en-
sure that the highest standard of research can be attained. 
There is a need to utilize and maximize current and fu-
ture investments into cohort studies in order to generate 
greatest benefit to the public and scientific community 
alike. It is hoped that these guidelines will maximize these 
investments through the considered understanding of ex-
isting data, repurposing of cohorts, and establishment and 
efficient design of future cohorts that include anchoring 
data points to past cohorts and enabling harmonization of 
data across studies, geographies, and time points which 
will translate into a robust data source for future research.
These guidelines were developed by a consensus group 
of experts from across Europe and represent the opinions 
of the participants. The consensus group was funded by 
the JPND and was developed through a series of work-
shops.
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